View More Recent Stories
-
Genmab A/S (GMAB) Reports 2024 Net Sales of DARZALEX of $11.67B
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
RBC report: Biotech faces both uncertainty and growth opportunities in 2025
-
Genmab A/S (GMAB) PT Raised to $48 at BMO Capital
-
Genmab A/S (GMAB) PT Lowered to $27 at Leerink Partners
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab A/S (GMAB) Reports Q3 Net sales of DARZALEX of $3.01B
-
TD Cowen Reiterates Hold Rating on Genmab A/S (GMAB)
-
Redburn-Atlantic Starts Genmab A/S (GEN:DC) (GMAB) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab A/S (GMAB) PT Lowered to $50 at Truist Securities
-
Morgan Stanley Resumes Genmab A/S (GMAB) at Equalweight
-
JPMorgan Downgrades Genmab A/S (GEN:DC) (GMAB) to Neutral
-
Genmab A/S (GMAB) Receives Second EU Approval for TEPKINLY
-
Genmab A/S (GMAB) PT Lowered to $30 at TD Cowen
-
Genmab A/S (GMAB) PT Lowered to $46 at BMO Capital
-
Genmab (GMAB) Updates 2024 Financial Guidance
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab A/S (GMAB) Reports Q2 New DARZALEX Sales of $2.88B
-
RBC Capital Upgrades Genmab A/S (GEN:DC) (GMAB) to Outperform
-
Genmab A/S (GMAB) Reports Positive CHMP Opinion for Epcoritamab
-
H.C. Wainwright Reiterates Buy Rating on Genmab A/S (GMAB)
-
Genmab A/S (GMAB) PT Raised to $47 at BTIG
-
Genmab A/S (GMAB) provides update on share buyback

